NPCE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neuropace Inc (NPCE) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company shows promising revenue growth and positive gross margin trends, the lack of significant trading signals, neutral sentiment from hedge funds and insiders, and weak technical indicators suggest that the stock does not currently present an optimal entry point. Additionally, the company's negative net income and EPS trends further weigh against a buy recommendation. It is better to monitor the stock for more favorable conditions.
The MACD is positive and expanding, indicating a slight bullish momentum. However, the RSI is neutral at 51.946, and moving averages are converging, showing no clear trend. Support and resistance levels are close to the current price, suggesting limited immediate upside potential.
Revenue growth of 23.86% YoY in Q4 2025 and gross margin improvement to 77.4%. Analysts maintain a Buy rating with a price target of $19, implying potential upside.
No recent news or significant trading activity from hedge funds, insiders, or Congress. Stock trend analysis suggests limited short-term upside with potential declines in the next week.
In Q4 2025, revenue increased to $26.59M, up 23.86% YoY, while net income dropped to -$2.73M (-48.02% YoY). EPS fell to -$0.08 (-55.56% YoY), and gross margin improved to 77.4% (+2.64% YoY).
Analysts maintain a Buy rating with a $19 price target, citing expected core revenue growth of 20%-22% in 2026.
